PARIS & FORT WORTH, Texas—Eyevensys, a privately held clinical-stage biotechnology company developing non-viral gene therapies for retinal and other ophthalmic diseases, announced that it has completed a $30 million Series B financing. The round was led by Boehringer Ingelheim Venture Fund and included participation from existing investors Pontifax, Bpifrance, CapDecisif, and Inserm Transfert, as well as new investors, the Global Health Sciences (GHS) Fund (Quark Venture LP and GF Securities) and Pureos Bioventures. The company said it will use the funds to continue the development of its clinical lead candidate EYS606 for the treatment of chronic non-infectious uveitis (NIU), including the launch of its Electro Study. 

Read more